Translational Software Showcasing New Pediatric Pharmacogenomic Solution at AMP17
Translational Software, Inc. has co-developed a pediatric pharmacogenomics (PGx) solution in collaboration with Inova Genomics Laboratory, part of the Inova Translational Medicine Institute, to help determine safe and effective medication prescribing and dosing.
With the clinical use of pediatric-based PGx lagging behind corresponding adult applications, the newly available pediatric PGx solution and testing panel provides much needed genotype-guided dosing for pediatric patients. Seven actionable genes are available for analysis to determine how a pediatric patient will respond to certain prescription medications, with actionable prescribing information for 24 drugs. The testing panel includes genes which can influence the metabolism of anti-cancer agents, antidepressants, cardiovascular and gastrointestinal drugs, certain opioids and more.
Translational Software’s proprietary PGx knowledge base classifies and interprets the raw genetic data from the pediatric PGx panel to generate a personalized, clinically actionable report with concise molecular intelligence and critical alerts regarding drug efficacy, toxicity, and known interactions to guide clinical decision making. The report includes educational information on the maturation trajectories of genes tested and the indications for each drug by age group. The PGx results of a single genetic test can be used to help guide treatment decisions throughout the patient’s lifetime, serving as a valuable once-in-a-lifetime diagnostic tool for precision medicine.
The Food and Drug Administration’s announcement earlier this year restricting use of all prescription medications containing codeine or tramadol in children under 12, and cautioning usage in 12 to 18 year olds with specific medical conditions, underscores the importance and value of PGx testing to identify the likely efficacy or toxicity of a medication for pediatric patients. With growing evidence linking drug response to genetic variability, and with costs decreasing rapidly for an array of genomic tests – including the CYP2D6 genotype test for codeine toxicity – use of PGx testing is growing in adoption to inform pediatric prescribing and guide precise patient therapies.
Technologies developed by TSI, including a PGx-based application programming interface, and a reporting application called MedsReview that integrates drug-drug and drug-gene data into a single view within the clinical workflow, represent the cornerstone for PGx implementation in the clinical setting, connecting laboratory testing partners, the clinical community and information system vendors seeking to ensure precise medical treatment with less trial and error. The company’s PGx knowledge platform has been used to provide over one million PGx recommendations to 100 laboratories and hospitals, and 20,000 physicians.